ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Samsung BioLogics trading suspended after fraud ruling

South Korean financial regulator orders delisting review

Samsung BioLogics breached accounting rules before its stock exchange listing in 2016, according to South Korea's top financial regulator.

SEOUL -- South Korea's financial regulator suspended share trading of Samsung BioLogics on Wednesday and fined the world's third largest contract drugmaker 8 billion won ($7.05 million), after ruling that it had committed accounting fraud in 2015 to inflate its value ahead of an initial public offering in 2016.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more